Carolina Wealth Advisors LLC Acquires 1,251 Shares of Novo Nordisk A/S (NYSE:NVO)

Carolina Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 308.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,656 shares of the company’s stock after acquiring an additional 1,251 shares during the period. Carolina Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $142,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $25,000. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $42,000. M&R Capital Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 260.5% in the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after buying an additional 297 shares during the period. Finally, Dunhill Financial LLC increased its stake in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after purchasing an additional 311 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of several research reports. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Trading Up 2.2 %

Novo Nordisk A/S stock opened at $82.99 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $99.26 and a two-hundred day moving average price of $118.18. The firm has a market capitalization of $372.42 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $80.05 and a 52-week high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.